MX345883B - Composiciones de peptidos en nanoparticulas. - Google Patents
Composiciones de peptidos en nanoparticulas.Info
- Publication number
- MX345883B MX345883B MX2014002418A MX2014002418A MX345883B MX 345883 B MX345883 B MX 345883B MX 2014002418 A MX2014002418 A MX 2014002418A MX 2014002418 A MX2014002418 A MX 2014002418A MX 345883 B MX345883 B MX 345883B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- linker
- nanoparticles
- amino acid
- core
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000002105 nanoparticle Substances 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 239000003446 ligand Substances 0.000 abstract 3
- 125000000837 carbohydrate group Chemical group 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000004065 semiconductor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Manufacturing & Machinery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a nanopartículas y composiciones que comprenden las nanopartículas, así como métodos para la administración intracelular de péptidos, y métodos de producción de nanopartículas y productos relacionados. Las nanopartículas comprenden un núcleo que comprende un metal y/o un átomo semiconductor, y una corona que comprende una pluralidad de ligandos unidos covalentemente al núcleo, en donde al menos un primer ligando de la pluralidad comprende una porción de carbohidrato que está unida covalentemente al núcleo a través de un primer enlazador, y en donde al menos un segundo ligando de la pluralidad comprende un péptido de elección que está unido covalentemente al núcleo a través de un segundo enlazador. El segundo enlazador comprende una porción peptídica y una porción no peptídica, en donde la porción peptídica del segundo enlazador comprende la secuencia de X1X2Z1, en donde: X1 es un aminoácido seleccionado de A y G; X2 es un aminoácido seleccionado de A y G, y Z1 es un aminoácido seleccionado de Y y F.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161531745P | 2011-09-07 | 2011-09-07 | |
PCT/EP2012/067561 WO2013034726A1 (en) | 2011-09-07 | 2012-09-07 | Nanoparticle-peptide compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002418A MX2014002418A (es) | 2014-10-13 |
MX345883B true MX345883B (es) | 2017-02-22 |
Family
ID=46829760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002418A MX345883B (es) | 2011-09-07 | 2012-09-07 | Composiciones de peptidos en nanoparticulas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9598479B2 (es) |
EP (1) | EP2753360B1 (es) |
JP (1) | JP6077544B2 (es) |
KR (1) | KR102001269B1 (es) |
CN (1) | CN103917249B (es) |
AU (1) | AU2012306243B2 (es) |
BR (1) | BR112014005242B1 (es) |
EA (1) | EA025758B1 (es) |
ES (1) | ES2627507T3 (es) |
IN (1) | IN2014MN00433A (es) |
MX (1) | MX345883B (es) |
WO (1) | WO2013034726A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
AU2012306258A1 (en) * | 2011-09-07 | 2014-04-17 | Immunotope, Inc. | Nanoparticle tumour vaccines |
US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
AU2014343379B2 (en) | 2013-11-04 | 2019-02-14 | Uti Limited Partnership | Methods and compositions for sustained immunotherapy |
CN107050444B (zh) * | 2014-07-25 | 2020-08-28 | 武汉博沃生物科技有限公司 | 轮状病毒多糖-蛋白结合疫苗及其制备方法 |
CN106668853A (zh) * | 2014-07-25 | 2017-05-17 | 武汉博沃生物科技有限公司 | 一种肺炎球菌缀合疫苗及其制备方法 |
CN104225589B (zh) * | 2014-07-25 | 2018-02-09 | 武汉博沃生物科技有限公司 | 一种缀合疫苗及其制备方法 |
KR101694121B1 (ko) | 2014-10-28 | 2017-01-10 | (주)헵틸와이 | 이중 가교구조의 생체친화형 다공성 시트 및 그 제조방법 |
KR20160067472A (ko) | 2014-12-04 | 2016-06-14 | (주)헵틸와이 | 생체친화형 섬유상 매트릭스, 이를 포함하는 마스크 팩 및 그 제조방법 |
CN107847582A (zh) | 2015-05-06 | 2018-03-27 | 优迪有限合伙公司 | 用于持续疗法的纳米颗粒组合物 |
GB2541166A (en) * | 2015-07-24 | 2017-02-15 | Midatech Ltd | Nanoparticle-based liver-targeting therapy and imaging |
AU2018206291A1 (en) | 2017-01-03 | 2019-07-25 | Emergex Vaccines Holding Limited | Universal influenza vaccine compositions |
KR102015805B1 (ko) * | 2017-05-11 | 2019-08-29 | 서울대학교산학협력단 | 유기 반도체 물질의 자기조립 나노구조체 및 제조방법 |
BR112020005565A2 (pt) | 2017-09-21 | 2020-10-06 | Emergex Vaccines Holding Limited | peptídeos associados a mhc de classe i para prevenção e tratamento de vírus zika |
AU2019205627B2 (en) | 2018-01-06 | 2024-05-09 | Emergex Vaccines Holding Limited | MHC class I associated peptides for prevention and treatment of multiple flavi virus |
SG11202009147UA (en) | 2018-03-29 | 2020-10-29 | Emergex Vaccines Holding Ltd | Vaccine compositions |
US20210283237A1 (en) | 2018-03-29 | 2021-09-16 | Emergex Vaccines Holding Limited | Vaccine compositions |
US20210299241A1 (en) | 2018-05-18 | 2021-09-30 | Emergex Vaccines Holding Limited | Reverse peptide vaccine |
RU2695135C1 (ru) * | 2018-07-11 | 2019-07-22 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства | Двухуровневая микрогранулированная форма терапевтического пептида для перорального применения и способ ее получения |
GB201820470D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Antifolate-carrying nanoparticles and their use in medicine |
GB201820471D0 (en) * | 2018-12-14 | 2019-01-30 | Midatech Ltd | Nanoparticle-based therapy of inflammatory disorders |
EP3909612A1 (en) | 2020-05-12 | 2021-11-17 | Life Science Inkubator Betriebs GmbH & Co. KG | Composition of nanoparticles |
GB202008250D0 (en) | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
JP2024507808A (ja) | 2021-02-16 | 2024-02-21 | エマージェクス ヴァクシーンズ ホールディング リミテッド | 逆ペプチド |
CN113209046B (zh) * | 2021-05-08 | 2022-09-09 | 中国人民解放军陆军军医大学 | 一种CoSe@BSA纳米粒子药物组合物及其制备方法和应用 |
WO2022253917A1 (en) | 2021-06-02 | 2022-12-08 | Emergex Vaccines Holding Limited | Human coronavirus 229e derived peptides |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
IL158140A0 (en) * | 2003-09-25 | 2004-03-28 | Hadasit Med Res Service | Multiepitope polypeptides for cancer immunotherapy |
ES2242528B1 (es) | 2004-03-25 | 2006-12-01 | Consejo Sup. Investig. Cientificas | Nanoparticulas magneticas de metales nobles. |
EP2330208B1 (en) | 2004-05-24 | 2017-10-18 | Midatech Ltd. | Nanoparticles comprising RNA ligands |
ES2625905T3 (es) * | 2004-10-01 | 2017-07-20 | Midatech Ltd. | Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores |
CN101123990A (zh) * | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒,和免疫原性结构 |
CA2617869C (en) * | 2005-08-04 | 2017-02-14 | Thomas William Rademacher | Nanoparticles comprising antibacterial ligands |
CA2652759C (en) * | 2006-04-13 | 2014-07-08 | Midatech Limited | Nanoparticles for providing immune responses against infectious agents |
EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
JP5661735B2 (ja) * | 2009-04-01 | 2015-01-28 | ユニバーシティ オブ マイアミ | ワクチン組成物及びその使用方法 |
US9132178B2 (en) | 2009-08-26 | 2015-09-15 | Immunotope, Inc. | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer |
EP2305310A1 (en) | 2009-09-25 | 2011-04-06 | Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE | Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents |
TWI485245B (zh) | 2010-01-25 | 2015-05-21 | Oncotherapy Science Inc | 經修飾之melk胜肽及含此胜肽之疫苗 |
AU2012306258A1 (en) | 2011-09-07 | 2014-04-17 | Immunotope, Inc. | Nanoparticle tumour vaccines |
-
2012
- 2012-09-07 EA EA201490415A patent/EA025758B1/ru not_active IP Right Cessation
- 2012-09-07 BR BR112014005242-5A patent/BR112014005242B1/pt active IP Right Grant
- 2012-09-07 AU AU2012306243A patent/AU2012306243B2/en active Active
- 2012-09-07 KR KR1020147009090A patent/KR102001269B1/ko active IP Right Grant
- 2012-09-07 ES ES12756725.3T patent/ES2627507T3/es active Active
- 2012-09-07 WO PCT/EP2012/067561 patent/WO2013034726A1/en active Application Filing
- 2012-09-07 EP EP12756725.3A patent/EP2753360B1/en active Active
- 2012-09-07 US US14/343,083 patent/US9598479B2/en active Active
- 2012-09-07 JP JP2014529001A patent/JP6077544B2/ja active Active
- 2012-09-07 MX MX2014002418A patent/MX345883B/es active IP Right Grant
- 2012-09-07 IN IN433MUN2014 patent/IN2014MN00433A/en unknown
- 2012-09-07 CN CN201280049979.0A patent/CN103917249B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014527960A (ja) | 2014-10-23 |
EP2753360B1 (en) | 2017-04-26 |
CN103917249A (zh) | 2014-07-09 |
BR112014005242A2 (pt) | 2018-06-05 |
AU2012306243B2 (en) | 2016-10-20 |
JP6077544B2 (ja) | 2017-02-08 |
US20140341938A1 (en) | 2014-11-20 |
EP2753360A1 (en) | 2014-07-16 |
IN2014MN00433A (es) | 2015-06-19 |
AU2012306243A1 (en) | 2014-03-13 |
MX2014002418A (es) | 2014-10-13 |
CN103917249B (zh) | 2016-11-09 |
ES2627507T3 (es) | 2017-07-28 |
KR20140069101A (ko) | 2014-06-09 |
BR112014005242B1 (pt) | 2022-07-26 |
KR102001269B1 (ko) | 2019-07-17 |
WO2013034726A1 (en) | 2013-03-14 |
US9598479B2 (en) | 2017-03-21 |
EA201490415A1 (ru) | 2014-08-29 |
EA025758B1 (ru) | 2017-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX345883B (es) | Composiciones de peptidos en nanoparticulas. | |
AU2020202093A1 (en) | Oligonucleotide-ligand conjugates and process for their preparation | |
PH12015502180A1 (en) | Wt1-antigen peptide conjugate vaccine | |
NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
PH12014502010A1 (en) | Bispecific antibodies against human tweak and human il17 and uses thereof | |
MX340558B (es) | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. | |
IN2014CN04160A (es) | ||
MX2013007559A (es) | Composicion farmaceutica de complejo de anticuerpo anti-digoxigenina y digoxigenina que se conjuga a un peptido. | |
GB2494787A (en) | Neuro-protective effects of adelostemma gracillimum and its isolated compounds | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
EP3839049A3 (en) | Antibodies, variable domains & chains tailored for human use | |
MY196510A (en) | Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors | |
EP3513794A3 (en) | Fucose analogs for inhibition of protein fucosylation in vivo | |
IL219801A (en) | Anti-a4 antibody. 4c isolates, vectors encoded by them, methods of preparation, preparations containing them and their use | |
WO2015063747A3 (en) | Peptide inhibitors of tead/yap-taz interaction | |
MX2014003278A (es) | Composiciones detergentes que comprenden sistemas surfactantes primarios que comprenden surfactantes con base de isoprenoide altamente ramificados y otros surfactantes. | |
UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
PL400162A1 (pl) | Nowe kompleksy rutenu, ich zastosowanie w reakcjach metatezy oraz sposób prowadzenia reakcji metatezy | |
MX2014002764A (es) | Vacunas en nanoparticulas para tumor. | |
UA115425C2 (uk) | Фармацевтична композиція, що містить інозит | |
IN2015DN03206A (es) | ||
IN2014DN09367A (es) | ||
MX2014002625A (es) | Nuevas composiciones para la produccion de poliamidas coladas. | |
GB201303865D0 (en) | Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein | |
PH12015501033A1 (en) | Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |